

Outcome of Graves' Disease and Associated Genetic Predisposition: A Systematic Review of Literature

Md. Ikhsan Mokoagow¹, Ahmad Zufar Manthovani², Marina Epriliawati¹

¹Division of Endocrinology, Metabolism, and Diabetes, Departement of Internal Medicine, Fatmawati Hospital, Jakarta

²Faculty of Medicine, Universitas Islam Negeri Syarif Hidayatullah Jakarta

Abstract

Background: Graves' disease (GD) is an autoimmune hyperthyroidism that primarily affects the thyroid gland. The susceptibility, activity, and risk of recurrence of GD may be influenced by various genetic factors, which can interact with environmental triggers to precipitate disease relapse. This review examines the literature on the genetic predisposition to GD recurrence. **Methods:** Literature from PubMed, EBSCOhost, and SCOPUS were searched. Three reviewers performed study selection and critical appraisal. **Result:** Five studies were selected. The literature indicates a risk of relapse in PTPN22, CTLA-4, TSH-R, IL-21, KREC, and HLA gene abnormalities. **Conclusion:** Several genes are associated with GD relapse. However, predicting relapse risk requires consideration of multiple factors beyond genetic predisposition.

PROSPERO registration number: CRD42024456285

Keywords: Graves' Disease, Relapse, Genetic predisposition to disease, interleukin-21, CTLA-4 Antigen, Thyrotropin

1. Introduction

Graves' disease (GD) is the most common cause of hyperthyroidism, which primarily affects the thyroid gland. It is an autoimmune disease that is precipitated by environmental factors like exposure to iodine, stress, smoking, infection, postpartum, and also immune reconstitution after *Highly Active Antiretroviral Therapy* (HAART). Graves' disease accounts for 20-30 annual cases per 100,000 individuals in iodine-rich parts of the world every year, which affects 3% of women and 0.5% of males all over the world.^{1,2}

The Predisposition to GD appears to be influenced by multiple genes. It is considered as Human Leukocyte Antigens (*HLA*) *class II*-associated disorder, and several genes are also involved in the development of Graves' disease such as *CTLA-4*, *TSHR*, Thyroglobulin gene (*Tg*), *CD40*, *PTPN22*, *CD25*, *FOXP3*, and *VDR*.³⁻⁸ GD can be managed through antithyroid drugs (ATD), radioactive iodine therapy or surgical intervention. While antithyroid drugs effectively control the symptoms of thyrotoxicosis, they do not address the underlying cause of GD, leading to frequent relapses.^{1,9}

In individuals with a genetic predisposition, specific environmental risk factors exposure can trigger the production of autoantigens against the Thyroid Stimulating Hormone (TSH) receptor, leading to the development or relapse of the disease.¹⁰ We aimed to systematically review the available research on the genetic predisposition to relapse of GD, providing a brief overview of the genes involved in disease relapse, its mechanisms, and prediction of relapse.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

2. Method


Initially, we searched for reviews on the outcome related to the relapse of Graves' disease and its associated genetic predisposition on the International Prospective Register of Systematic Reviews (PROSPERO). We found no existing systematic review. As the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement recommended, this systematic review was registered on PROSPERO (www.crd.york.ac.uk/PROSPERO).

We conducted a literature search on April 4th, 2024, using PubMed, EBSCOhost, and Scopus with the keywords from Table 1. The search was restricted to English published within the last ten years. We aimed to identify all observational, comparative, meta-analyses, and systematic reviews. A total of 12 studies were identified. Three reviewers carried out the study selection and critical appraisal to assess eligibility. Seven studies were excluded due to having different objectives. Hence, five studies were included. The selected articles were critically reviewed using the Newcastle-Ottawa Scale (NoS). The corresponding flowchart is shown in Figure 1.

Table 1. Keywords for advance searching

Objectives	Keywords
Graves' Disease	Graves' disease OR Graves disease OR Toxic diffuse goiter OR Toxic diffuse goiter OR Basedow
AND	
CD40	CD40 OR CD40 Molecule OR Bp50 OR TNFRSF5 OR P50 OR Tumor Necrosis Factor Receptor Superfamily Member 5 OR CD40 Molecule, TNF Receptor Superfamily Member 5 OR CD40L Receptor OR Tumor Necrosis Factor Receptor Superfamily, Member 5 OR B Cell Surface Antigen CD40 OR B Cell-Associated Molecule OR CD40 Antigen
CTLA-4	CTLA-4 OR Cytotoxic T-Lymphocyte Associated Protein 4 OR Cytotoxic T-Lymphocyte Protein 4 OR Cytotoxic T Lymphocyte Associated Antigen 4 Short Spliced Form OR Cytotoxic T-Lymphocyte-Associated Serine Esterase-4 OR Cytotoxic T-Lymphocyte-Associated Antigen 4 OR CD152
Thyroglobulin gene	TG OR Thyroglobulin OR AITD3 OR TGN
TSHR	TSHR OR Thyroid Stimulating Hormone Receptor OR Thyroid-Stimulating Hormone Receptor OR TSH Receptor OR TSH-R OR Thyrotropin Receptor OR LGR3 OR HTSHR-I OR CHNG1
PTPN22	PTPN22 OR Protein Tyrosine Phosphatase Non-Receptor Type 22 OR Protein Tyrosine Phosphatase, Non-Receptor Type 22 (Lymphoid) OR Tyrosine-Protein Phosphatase Non-Receptor Type 22 OR PTPN22.5 OR PTPN22.6 OR PTPN8 OR Protein Tyrosine Phosphatase, Non-Receptor Type 8 OR Lyp OR Lymphoid-Specific Protein Tyrosine Phosphatase OR Lymphoid Phosphatase
FOXP3	FOXP3 OR Forkhead Box P3 OR Forkhead Box Protein P3 OR DIETER OR XPID OR AIID OR PIDX OR IPEX OR JM2 OR SCURFIN
VDR	VDR OR Vitamin D Receptor OR Vitamin D (1,25- Dihydroxyvitamin D3) Receptor OR Vitamin D3 Receptor OR 1,25- Dihydroxyvitamin D3 Receptor OR NR111 OR PPP1R163 OR Protein Phosphatase 1, Regulatory Subunit 163
CD25	CD25 OR IL2RA OR Interleukin 2 Receptor Subunit Alpha OR Interleukin-2 Receptor Subunit Alpha OR IL-2 Receptor Subunit Alpha OR IL-2R Subunit Alpha OR TAC Antigen OR IDDM10 OR IL2R OR P55 OR TCGFR OR IL2-RA
AND	
Relapse	Relapse OR Recurrence

Figure 1. Study's method flowchart



3. Result

Five studies were selected, comprising 2 retrospective cohort studies, 1 prospective cohort study, and 2 case-control studies. The selected articles showed a risk of recurrence in *PTPN22*, *CTLA-4*, *TSH-R*, *IL-21*, *KREC*, and *HLA* gene abnormalities (Table 2). However, no studies within the specified period supported an association with recurrence for other genes. Literature assessment using the Newcastle-Ottawa Scale, converted to the Agency for Healthcare Research and Quality (AHRQ) standards, indicated that all selected studies were of good quality (Table 3).

Table 2. Selected-studies description

No	Title	Author	Years	Total Subjects	Design	Results
1	Recurrence of Graves' Disease: What Genetics of HLA and PTPN22 Can Tell Us	Vejrazkova et al.	2021	206 patients	Retrospective Cohort Study	The risk HLA haplotype <i>DRB1*03-DQAI*05-DQB1*02</i> was more frequent in our GD patients are more numerous than the general European population. During long-

						<p>term retrospective follow-up (many-year to lifelong perspective), 87 patients relapsed, and 26 achieved remission lasting over two years, indicating a 23% success rate for conservative treatment of the disease. In 93 people, the success of conservative treatment could not be evaluated (thyroidectomy immediately after the first attack or ongoing antithyroid therapy). Of the examined genes, the HLA-<i>DQA1</i>*05 variant reached statistical significance in terms of the ability to predict relapse ($p=0.03$). Combinations with either both other HLA risk genes forming the risk haplotype <i>DRB1</i>*03-<i>DQA1</i>*05-<i>DQB1</i>*02 or with the <i>PTPN22</i> SNP did not improve the predictive value</p>
2	The Role of Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) Gene, Thyroid Stimulating Hormone Receptor (TSHR) Gene and Regulatory T-cells as Risk Factors for Relapse in Patients with Graves' Disease	Eliana et al.	2017	144 patients	Case-Control Study	<p>The analysis of this study demonstrated that there was a correlation between relapse of disease and family factors ($p=0.008$), age at diagnosis ($p=0.021$), 2nd degree of Graves' ophthalmopathy ($p=0.001$), enlarged thyroid gland, which exceeded the lateral edge of the sternocleidomastoid muscles ($p=0.040$), duration of remission period ($p=0.029$), GG genotype of <i>CTLA-4</i> gene on the nucleotide 49 at codon 17 of exon 1 ($p=0.016$), CC genotype of <i>TSHR</i> gene on the rs2268458 of intron 1 ($p=0.003$), the number of regulatory T cells</p>

						(p=0.001), and TRAb levels (p=0.002).
3	Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves' hyperthyroidism	Vos et al.	2016	263 patients	Prospective Cohort Study	Thirty-seven percent of 178 patients had recurrent Graves' hyperthyroidism within two years after antithyroid drug withdrawal. In Cox regression, lower age, higher serum free T4, higher serum thyrotropin-binding inhibitor immunoglobulin, larger goiter sizes at diagnosis, PTPN22 C/T polymorphism, and HLA subtypes DQB1*02, DQA1*05, and DRB1*03 were independent predictors for recurrence. Two simplified predictive models were constructed based on HRs of the multivariate model, called the Graves' Recurrent Events After Therapy (GREAT) score for clinical markers and the GREAT+ score for the combination of clinical and genetic markers. The GREAT and GREAT+ scores were divided into classes according to recurrence rates. Higher recurrence rates were observed in GREAT score class III (68%) compared with class II (44%) or class I (16%). The GREAT+ score showed much higher rates of recurrence in class IV+ (84%) compared with class III+ (49%), class II+ (21%), and class I+ (4%). The most significant benefit of the GREAT+ score is in GREAT score class II: addition of genotypes changes recurrence risk (and thereby management) in 38%.
4	Association between IL-21	Zeng et al.	2014	423 patients	Case-Control Study	The results indicated that the frequencies of the

	gene rs907715 polymorphisms and Graves' disease in a southern Chinese population					GG genotype and the G allele in GD patients were significantly increased compared to those in the controls ($P=6.7 \times 10^{-3}$ and $P=2.0 \times 10^{-5}$, respectively). In addition, the frequency of the AA genotype was much lower in the patient group compared to the control group (16.6 vs. 34.0%; $P=4.0 \times 10^{-5}$). Furthermore, the G allele of rs907715 was associated with relapse in GD patients.
5	Expansion of the immature B lymphocyte compartment in Graves' disease	Lane et al.	2023	132 patients	Retrospective Cohort Study	Circulating KRECs were higher in GD vs. controls ($P = 1.5 \times 10^{-9}$) and demonstrated a positive correlation to thyroid hormones and autoantibodies (free thyroxine: $P = 2.14 \times 10^{-5}$, $\rho = .30$; free triiodothyronine: $P = 1.99 \times 10^{-7}$, $\rho = .37$; thyroid stimulating hormone receptor autoantibodies: $P = 1.36 \times 10^{-5}$, $\rho = .23$). Higher KRECs in GD patients 6-10 weeks after ATD withdrawal were associated with relapse of hyperthyroidism at one year ($P = .04$). The KRECs were positively correlated to the total CD19+ B cell count ($P = 3.2 \times 10^{-7}$).

Table 3. New Castle Ottawa Scape and Quality Assessment

No	Author	Design	Selection (4)	Comparability (1)	Outcome/Exposure (3)	Total	Quality
1	Vejrazkova et al.	Retrospective Cohort Study	3	1	3	8	Good
2	Eliana et al.	Case-Control Study	3	1	3	7	Good
3	Vos et al.	Prospective Cohort Study	4	1	3	8	Good
4	Zeng et al.	Case-Control Study	3	1	3	7	Good
5	Lane et al.	Cohort Study	3	1	3	7	Good

4. Discussions

4.1 Graves' Disease Relapse

Relapse in GD is defined as the reappearance of hyperthyroidism symptoms, along with laboratory results showing serum T₄ and/or T₃ levels above the normal range. Relapse occurs most likely within the 6-12 months or later after the withdrawal of ATD. All patients should be monitored for relapse during the first year after completing treatment and then annually thereafter. Patients with severe hyperthyroidism, large goiters, or consistently high TSH-R-Antibody titers are at the highest risk of relapse after treatment cessation.^{2,11}

4.2 Human Leukocyte Antigen (HLA) Complex

The Human Leukocyte Antigen (*HLA*) complex is associated with the autoimmune nature of GD. The *HLA Class II region*, located within the Major Histocompatibility Complex (MHC) on chromosome 6p21, plays a crucial role in the autoimmune process. *HLA* class II molecules are expressed on the surface of B cells, macrophages, dendritic cells, and activated T cells. They are involved in the processing and presentation of exogenous antigens. This region is highly polymorphic and considered critical in developing autoimmune diseases. Within the *HLA*, the DR3 haplotype (*DQB1*02, DQA1*0501, DRB1*03*) predisposes to GD due to strong linkage disequilibrium among the *DQA1*, *DQB1*, and *DRB1* loci. In contrast, the DR7 haplotype (*DQA1*0201, DQB1*0302, DRB1*07* or *DQA1*0201, DQB1*02, DRB1*07*) appears to offer protection (Antonelli et al).^{3,12,13}

Vos et al., in the prospective cohort study, stated that HLA Class II haplotypes DRB103, DQA105, and DQB102 are well-established as being associated with an elevated risk of developing Graves' hyperthyroidism in Caucasians. The research has identified that these specific polymorphisms—*HLA DRB103, DQA105, and DQB102*—are significant predictors of recurrence following antithyroid drug therapy. Another study has examined the association between recurrence risk and *HLA DQA1*05* and found no significant correlation. (Vos et al.).¹²

The *DRB1*03, DQA1*05, and DQB1*02* allelic groups have proven to be predictors of the development and recurrence of GD. The *HLA-DQA105* variant and the *DRB103-DQA105-DQB102* haplotype were more common in GD patients than in the general European population. However, the gene tested individually is not a reliable predictor of relapse in the Czech population. A comparison with some reference European populations suggests a higher minor allele frequency in the GD patients. The *HLA-DQA1*05* allelic group was significantly associated with relapse or prolonged unsuccessful conservative treatment (Vejrazkova et al.).¹⁰

4.3 PTPN22

The Protein Tyrosine Phosphatase-22 (*PTPN22*) gene encodes the lymphoid tyrosine phosphatase (*LYP*) protein, which acts as a potent negative regulator of T-cell receptor signaling. *PTPN22* plays a role in the pathogenesis of GD. The *PTPN C/T* Single Nucleotide Polymorphism (SNP) (*rs2476601*) is also associated with Graves' hyperthyroidism and recurrence rate (Vos et al). The *PTPN22* genetic variant *rs2466601* has been identified as a potential predictor of Graves' disease and was included in the Graves' Events After Therapy (GREAT+) score and *HLA* variants. However, the study

by Vejrazkova et al. did not demonstrate the predictive potential of the *PTPN22* variant for disease recurrence. Therefore, this gene cannot be relied upon to predict relapse in the Czech population.^{10,12–14}

The *PTPN22* *R620W* SNP is associated with Graves' disease and causes a functional change in the *LYP* protein. The tryptophan-bearing *LYP* allele cannot bind with C-terminal src kinase (Csk), an inhibitory complex partner that regulates key T cell receptor signaling kinases. Paradoxically, this mutation enhances the protein's ability to inhibit T cells, making it a gain-of-function mutation. This reduced T cell signaling may allow self-reactive T cells to escape thymic deletion and persist in the periphery. Ethnic studies have shown varying associations, likely due to founder effects or the absence of specific variants in different populations. For instance, the tryptophan variant of the *PTPN22* gene is not present in the Japanese population, suggesting it does not contribute to autoimmunity in this group (Jacobson et al.).⁵

4.4 CTLA-4

Cytotoxic T Lymphocyte-Associated Molecule 4 (*CTLA-4*) delivers a negative signal to T cells, regulating their transition to a state of non-responsiveness and tolerance, thereby controlling their proliferation. Polymorphism in the gene promoter, which controls gene transcription, may affect the *CTLA-4* level by changing the binding of transcription factors.^{15,16}

The *CTLA-4* gene consists of 3 introns and four exons. The Exon 1 of *CTLA-4* is demonstrated to have a role as a risk factor and relapse of autoimmune disease. The GG genotype of *CTLA-4* at nucleotide 49, codon 17 of exon one, is known to have a higher risk of relapse (Eliana et al.). The study from Wang et al. confirms that the *CTLA-4* genotypes are useful in predicting the relapse of GD after treatment cessation.^{15,16}

4.5 TSHR

The *TSHR* gene has long been considered a prime candidate gene for Graves' disease due to the presence of stimulating TSH receptor (*TSH-R*) autoantibodies, a hallmark of the disease. The *TSH-R* is expressed on the surface of thyroid epithelial cells and is located on the long arm of chromosome 14 (14q31). It binds to Thyroid Stimulating Hormone and triggers the production of thyroid hormones. Intron 1 of the *TSHR* gene functions as a regulator of RNA, influencing the initiation site for mRNA formation. Research findings have been inconsistent regarding the association between the *TSHR* gene and GD (Jacobson et al). However, a study by Eliana et al. found that GD patients with the CC genotype for the *TSHR* gene SNP *rs2268458* in intron 1 had a higher risk of relapse compared to those with the TT genotype.^{5,15}

4.6 IL-21

Interleukin-21 (*IL-21*) is located on chromosomes 4q26-27 and 16p11, close to *IL-2*, a region associated with autoimmune thyroid diseases. *IL-21* has been shown to play a crucial role in interactions among B cells, T cells, NK cells, and dendritic cells, potentially serving as a key cytokine linking innate and adaptive immune responses. Zhang et al. found a significant association between Graves' disease (GD) and polymorphisms in the *IL-21* gene region. Zeng et al. specifically identified that the *rs907715* variant in intron 3 of the *IL-21* gene is linked to GD susceptibility. Individuals carrying risk-associated G alleles are more susceptible to GD and tend to relapse after

treatment cessation. The biological mechanisms underlying the G allele's effects remain poorly understood.¹⁷⁻¹⁹

4.7 KREC

Kappa-deleting recombination excision circles (*KRECs*) are formed during B-cell development in cases where B lymphocytes fail to successfully rearrange the Ig kappa light chain genes (*IGK*) after the Ig heavy chain rearrangement. This results in the deletion of the constant kappa gene segment (*IGKC*) through recombination with the kappa-deleting element (*Kde*), a sequence located about 24 kb downstream. The recombination deletes portions of DNA, and the excised ends form circular DNA elements known as *KRECs*. Normally, cells with receptors for autoantigens and their *TRECs* or *KRECs* are deleted in central lymphoid organs after interacting with local epithelial cells. If central immune tolerance is impaired, many autoreactive T and B cells, along with their *TRECs* and *KRECs*, escape into circulation and target various organs, increasing the risk of autoimmunity.^{20,21}

KREC levels have been linked to disease status and activity in another B-cell-mediated autoimmune disorder. This suggests that *KRECs* might offer mechanistic insights into the immunopathology driving autoimmunity in Graves' disease and could also be associated with relevant clinical phenotypes or outcomes. A study conducted by Lane et al. is the first to report that higher *KREC* levels are associated with GD relapse or disease activity.²²

4.8 Other genes related to relapse of Graves' Disease

Other genes are found related to relapse, such as *CD40* with 3 polymorphisms (*rs745307*, *rs11569309*, and *rs3765457*). *CD40*, a crucial co-stimulatory molecule on antigen-presenting cells, plays a major role in T cell-dependent B cell activation. Polymorphisms that increase *CD40* expression could potentially trigger GD relapse by boosting the humoral response. Haplotype studies link *CD40* polymorphisms associated with GD outcomes to higher *CD40* mRNA expression levels.²³

The *TG* gene encodes thyroglobulin, a protein essential for thyroid hormone production. Elevated serum thyroglobulin levels are often observed in GD and have been linked to a higher relapse risk. Genetic variants in thyroid-specific genes may interact with immune-related genes, potentially influencing GD outcomes synergistically. *CD25*, *VDR*, and *FOXP3* genes are associated with the susceptibility to developing Graves' Disease. However, there is no specific information about these genes being associated with relapse of GD.^{4,6,8,23}

In conclusion, genes associated with Graves' disease relapse include *HLA*, *PTPN22*, *CTLA-4*, *TSHR*, *IL-21*, and *KREC*. While detected mutations in these genes may increase the risk of recurrence, genetic testing alone cannot be solely relied upon to predict relapse in an individual. Multiple factors need to be considered when predicting Graves' disease recurrence. Additionally, the tendency for each gene mutation varies based on geographical distribution, with the frequency and form of mutations differing across countries. In this review, we found limited recent research within the past ten years, which restricted the literature included in this systematic review. Further research on the genetic predisposition to Graves' disease relapse is necessary so that, in the future, genetic mapping in Graves' disease patients can more accurately predict outcomes.

Reference

1. Pokhrel B, Bhusal K. Graves Disease [Internet]. StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2023. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK448195/>
2. Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. *Eur Thyroid J* [Internet]. 2018;7(4):167–86. Available from: <https://etj.bioscientifica.com/view/journals/etj/7/4/ETJ490384.xml>
3. Antonelli A, Ferrari SM, Ragusa F, Elia G, Paparo SR, Ruffilli I, et al. Graves' disease: Epidemiology, genetic and environmental risk factors and viruses. *Best Pract Res Clin Endocrinol Metab* [Internet]. 2020;34(1):101387. Available from: <https://www.sciencedirect.com/science/article/pii/S1521690X20300142>
4. Zhou F, Liang Z, Wang X, Tan G, Wei W, Zheng G, et al. The VDR gene confers a genetic predisposition to Graves' disease and Graves' ophthalmopathy in the Southwest Chinese Han population. *Gene*. 2021 Aug;793:145750.
5. Jacobson EM, Tomer Y. The CD40, CTLA-4, thyroglobulin, TSH receptor, and PTPN22 gene quintet and its contribution to thyroid autoimmunity: back to the future. *J Autoimmun*. 2007;28(2–3):85–98.
6. Tan G, Wang X, Zheng G, Du J, Zhou F, Liang Z, et al. Meta-analysis reveals significant association between FOXP3 polymorphisms and susceptibility to Graves' disease. *J Int Med Res*. 2021 Apr;49(4):3000605211004199.
7. Mochizuki M, Amemiya S, Kobayashi K, Kobayashi K, Shimura Y, Ishihara T, et al. Association of the CTLA-4 gene 49 A/G polymorphism with type 1 diabetes and autoimmune thyroid disease in Japanese children. *Diabetes Care*. 2003 Mar;26(3):843–7.
8. Chu X, Pan C-M, Zhao S-X, Liang J, Gao G-Q, Zhang X-M, et al. A genome-wide association study identifies two new risk loci for Graves' disease. *Nat Genet*. 2011 Aug;43(9):897–901.
9. Kim H. Long-term management of Graves disease : a narrative review. 2023;40(1):12–22.
10. Vejrazkova D, Vcelak J, Vaclavikova E, Vankova M, Zajickova K, Vrbikova J, et al. Recurrence of Graves' Disease: What Genetics of HLA and PTPN22 Can Tell Us. *Front Endocrinol (Lausanne)*. 2021;12:761077.
11. Wang P-W, Chen I-Y, Juo S-HH, Hsi E, Liu R-T, Hsieh C-J. Genotype and Phenotype Predictors of Relapse of Graves' Disease after Antithyroid Drug Withdrawal. *Eur Thyroid J* [Internet]. 2013;1(4):251–8. Available from: <https://etj.bioscientifica.com/view/journals/etj/1/4/ETJ342621.xml>
12. Vos XG, Endert E, Zwinderman AH, Tijssen JGP, Wiersinga WM. Predicting the Risk of Recurrence Before the Start of Antithyroid Drug Therapy in Patients With Graves' Hyperthyroidism. *J Clin Endocrinol Metab*. 2016 Apr;101(4):1381–9.
13. Brand O, Gough S, Heward J. HLA , CTLA-4 and PTPN22 : the shared genetic master-key to autoimmunity? *Expert Rev Mol Med*. 2005 Oct;7(23):1–15.

14. Tomer Y. Mechanisms of autoimmune thyroid diseases: from genetics to epigenetics. *Annu Rev Pathol.* 2014;9:147–56.
15. Eliana F, Suwondo P, Asmarinah A, Harahap A, Djauzi S, Prihartono J, et al. The Role of Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) Gene, Thyroid Stimulating Hormone Receptor (TSHR) Gene and Regulatory T-cells as Risk Factors for Relapse in Patients with Graves Disease. *Acta Med Indones.* 2017 Jul;49(3):195–204.
16. Wang P-W, Chen I-Y, Liu R-T, Hsieh C-J, Hsi E, Juo S-HH. Cytotoxic T lymphocyte-associated molecule-4 gene polymorphism and hyperthyroid Graves' disease relapse after antithyroid drug withdrawal: a follow-up study. *J Clin Endocrinol Metab.* 2007 Jul;92(7):2513–8.
17. Zhang J, Xiao WX, Zhu YF, Muhali FS, Xiao L, Jiang WJ, et al. Polymorphisms of interleukin-21 and interleukin-21-receptor genes confer risk for autoimmune thyroid diseases. 2013;
18. Zeng H, Yan H, Zhang Z, Fang W, Ding R, Huang L, et al. Association between IL-21 gene rs907715 polymorphisms and Graves' disease in a Southern Chinese population. *Exp Ther Med.* 2014 Jul;8(1):213–8.
19. Jia HY, Zhang ZG, Gu XJ, Guo T, Cui B, Ning G, et al. Association between interleukin 21 and Graves' disease. *Genet Mol Res.* 2011 Oct;10(4):3338–46.
20. Chiarini M, Zanotti C, Serana F, Sottini A, Bertoli D, Caimi L, et al. T-cell Receptor and K-deleting Recombination Excision Circles in Newborn Screening of T- and B-cell Defects: Review of the Literature and Future Challenges. *J Public health Res.* 2013 Apr;2(1):9–16.
21. Mahtab S, Kar P, Saha S, Sreenivas V, Sottini A, Imberti L, et al. Central Immune Tolerance of T and B Cells in Patients With Idiopathic Hypoparathyroidism, T1D, and Autoimmune Thyroiditis. *J Endocr Soc.* 2019 Jun;3(6):1175–84.
22. Lane LC, Cheetham TD, Razvi S, Allinson K, Pearce SHS. Expansion of the immature B lymphocyte compartment in Graves' disease. *Eur J Endocrinol.* 2023 Aug;189(2):208–16.
23. Grixti L, Lane LC, Pearce SH. The genetics of Graves' disease. *Rev Endocr Metab Disord* [Internet]. 2024;25(1):203–14. Available from: <https://doi.org/10.1007/s11154-023-09848-8>